Renal Denervation for Uncontrolled Hypertension (RDNP-2012-02)
Primary Purpose
Hypertension
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Renal Denervation
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring renal denervation, blood pressure, cardiovascular risk, target organ damage, sympathetic activity
Eligibility Criteria
Inclusion Criteria:
- BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes)
- concurrent treatment with 2 anti-hypertensive drugs
Exclusion Criteria:
- renal artery anatomy ineligible for treatment
- eGFR <15mL/min/1.73m2 (using MDRD formula)
- individual has had myocardial infarction, unstable angina or cerebrovascular accident within 6 months of screening visit
- female participants of child bearing potential must have negative pregnancy test prior to treatment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Usual care
Renal Denervation Group
Arm Description
participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
participants randomised to undergo the renal denervation procedure
Outcomes
Primary Outcome Measures
blood pressure control
percentage of patients who achieve BP target at 6 months post intervention
Secondary Outcome Measures
number of drugs required to reach target blood pressure
number of drugs required to reach target blood pressure
time to achieve blood pressure target
time to achieve blood pressure target
change in sympathetic nerve activity
changes in muscle sympathetic nerve activity (MSNA), renal and whole body Noradrenaline (NA) spillover
Change in left ventricular function
Change in left Ventricular ejection fraction, diastolic filling
Change in Quality of Life
Change in Quality of life as assessed be relevant questionnaires
Change in Serum Biochemistry
Plasma Renin Activity, aldosterone levels, estimated Glomerular Filtration Rate(eGFR), inflammatory markers, fasting glucose, fasting insulin, C-peptide, Homeostasis Model Assessment (HOMA) index, Lipid profile
Change in markers of arterial stiffness
Change in markers of arterial stiffness as assessed by Augmentation Index (AI) and Pulse Wave Velocity (PWV)
Change in left ventricular structure
Change in left ventricular mass index
Change in Urine Biochemistry
Urinary albumin creatinine ratio (UACR), 24 hour urinary creatinine clearance, sodium
Full Information
NCT ID
NCT02016573
First Posted
December 16, 2013
Last Updated
November 4, 2018
Sponsor
Baker Heart and Diabetes Institute
1. Study Identification
Unique Protocol Identification Number
NCT02016573
Brief Title
Renal Denervation for Uncontrolled Hypertension
Acronym
RDNP-2012-02
Official Title
Renal Denervation for Uncontrolled Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Withdrawn
Why Stopped
No participants enrolled into study and protocol has been superseded
Study Start Date
December 2013 (Anticipated)
Primary Completion Date
April 2015 (Anticipated)
Study Completion Date
April 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baker Heart and Diabetes Institute
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a study investigating the safety and usefulness of the Renal Denervation Procedure in reducing high blood pressure in people whose blood pressure is not adequately controlled despite already being treated with 2 blood pressure lowering drugs. This study is designed to compare the effects renal denervation to a usual care group.
Detailed Description
This is a phase 4 randomised control trial of renal denervation for the treatment of uncontrolled hypertension.
Previous studies have shown that the renal denervation procedure is safe and effective in reducing blood pressure.
A total of 100 participants with uncontrolled blood pressure, treated with two blood pressure lowering medications will be recruited into the study. Patients will be assigned to one of two groups. Participants in Group 1 will be assigned to undergo the renal denervation procedure. Participants in group 2 will undergo usual care, receiving additional antihypertensive medication in an attempt to reach blood pressure targets.
The duration of this study is 36 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
renal denervation, blood pressure, cardiovascular risk, target organ damage, sympathetic activity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Usual care
Arm Type
No Intervention
Arm Description
participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
Arm Title
Renal Denervation Group
Arm Type
Experimental
Arm Description
participants randomised to undergo the renal denervation procedure
Intervention Type
Device
Intervention Name(s)
Renal Denervation
Other Intervention Name(s)
Symplicity Renal Denervation Catheter
Intervention Description
Renal Denervation Catheter
Primary Outcome Measure Information:
Title
blood pressure control
Description
percentage of patients who achieve BP target at 6 months post intervention
Time Frame
6 months post procedure
Secondary Outcome Measure Information:
Title
number of drugs required to reach target blood pressure
Description
number of drugs required to reach target blood pressure
Time Frame
baseline to 6 months
Title
time to achieve blood pressure target
Description
time to achieve blood pressure target
Time Frame
baseline to 6 months
Title
change in sympathetic nerve activity
Description
changes in muscle sympathetic nerve activity (MSNA), renal and whole body Noradrenaline (NA) spillover
Time Frame
baseline to 6 months
Title
Change in left ventricular function
Description
Change in left Ventricular ejection fraction, diastolic filling
Time Frame
baseline to 6 months
Title
Change in Quality of Life
Description
Change in Quality of life as assessed be relevant questionnaires
Time Frame
baseline to 6 months
Title
Change in Serum Biochemistry
Description
Plasma Renin Activity, aldosterone levels, estimated Glomerular Filtration Rate(eGFR), inflammatory markers, fasting glucose, fasting insulin, C-peptide, Homeostasis Model Assessment (HOMA) index, Lipid profile
Time Frame
baseline to 6 months
Title
Change in markers of arterial stiffness
Description
Change in markers of arterial stiffness as assessed by Augmentation Index (AI) and Pulse Wave Velocity (PWV)
Time Frame
baseline to 6 months
Title
Change in left ventricular structure
Description
Change in left ventricular mass index
Time Frame
baseline to 6 months
Title
Change in Urine Biochemistry
Description
Urinary albumin creatinine ratio (UACR), 24 hour urinary creatinine clearance, sodium
Time Frame
baseline to 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes)
concurrent treatment with 2 anti-hypertensive drugs
Exclusion Criteria:
renal artery anatomy ineligible for treatment
eGFR <15mL/min/1.73m2 (using MDRD formula)
individual has had myocardial infarction, unstable angina or cerebrovascular accident within 6 months of screening visit
female participants of child bearing potential must have negative pregnancy test prior to treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Markus P Schlaich, MD
Organizational Affiliation
Baker IDI Heart & Diabetes Institute
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
No data available
Learn more about this trial
Renal Denervation for Uncontrolled Hypertension
We'll reach out to this number within 24 hrs